| Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. | |
| | |
MedLine Citation:
|
PMID: 12010089 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Ziprasidone is a novel antipsychotic agent with a pharmacological profile distinct from that of other currently available novel or classical antipsychotics. In preclinical studies, ziprasidone was predicted to have efficacy against positive, negative and affective symptoms of schizophrenia with a favourable tolerability profile, including a low propensity to induce extrapyramidal adverse effects. The drug has been administered orally to >300 patients with an acute exacerbation of schizophrenia or schizoaffective disorder in published 4- to 6-week randomised, double-blind trials. When given twice daily, at dosages of between 80 and 160 mg/day, ziprasidone produced significantly greater improvements in overall symptomatology than placebo. In the largest study, ziprasidone 80 or 160 mg/day was also significantly more effective than placebo in reducing negative symptoms and, at 160 mg/day, was significantly more effective than placebo in improving depressive symptoms in patients with associated clinically significant depression. Data from a 4-week trial indicate that ziprasidone 160 mg/day has similar efficacy to haloperidol 15 mg/day. Ziprasidone 40 to 160 mg/day was more effective than placebo with respect to prevention of impending relapse and improvement of negative symptoms in 294 stable patients with chronic schizophrenia who were treated for up to 1 year. In addition, significantly more ziprasidone than haloperidol recipients achieved a negative symptom response in a 28-week study involving 301 stable patients with chronic or subchronic schizophrenia. In general, oral ziprasidone is well tolerated with an overall incidence of adverse events similar to placebo. Importantly, the drug has a low propensity to induce extrapyramidal effects and a negligible effect on bodyweight. Ziprasidone is associated with slight prolongation of the QTc interval; the clinical significance of this is not yet clear. The drug does not appear to be associated with sustained elevation of plasma prolactin concentrations. Preliminary data indicate that long-term oral ziprasidone treatment is well tolerated. Ziprasidone is the only novel antipsychotic currently available in a rapid-acting intramuscular formulation. Short-term treatment with intramuscular ziprasidone was effective and well tolerated in patients with acute agitation associated with psychosis. In addition, intramuscular ziprasidone reduced agitation scores by a significantly greater extent than haloperidol in a study involving patients with acute agitation associated with psychosis. CONCLUSIONS: Ziprasidone is a promising new antipsychotic that has shown significant efficacy in the oral treatment of patients with schizophrenia or schizoaffective disorder. The drug is well tolerated with a low propensity to induce extrapyramidal effects and a negligible effect on bodyweight. In addition, intramuscular ziprasidone shows efficacy and good tolerability in the treatment of acute agitation associated with psychotic disorders. |
| | |
Authors:
|
Nishan S Gunasekara; Caroline M Spencer; Gillian M Keating |
Related Documents
:
|
19341509 - Do atypical features affect outcome in depressed outpatients treated with citalopram? 20370959 - Impact of an educational workshop upon attitudes towards pharmacotherapy for delirium. 12870569 - Differential effect of quetiapine on depressive symptoms in patients with partially res... 9673859 - Neuroleptic malignant syndrome. recognition, prevention and management. 11436959 - Quetiapine treatment of children with tourette's syndrome: report of two cases. 17384319 - Cardiac and cerebrovascular morbidity and mortality associated with antipsychotic medic... 17244849 - Alexithymia in chronic fatigue syndrome: associations with momentary, recall, and retro... 22206079 - A randomized, double-blind, controlled comparative trial of the anti-aging properties o... 21116909 - Advances in treatment of cerebral vasospasm: an update. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Drugs Volume: 62 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 2002 |
Date Detail:
|
Created Date: 2002-05-15 Completed Date: 2002-09-17 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 1217-51 Citation Subset: IM |
Affiliation:
|
Adis International Limited, Auckland, New Zealand. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Antipsychotic Agents / adverse effects, pharmacokinetics*, pharmacology* Clinical Trials as Topic Drug Interactions Humans Injections, Intramuscular Piperazines / adverse effects, pharmacokinetics*, pharmacology* Psychotic Disorders / drug therapy* Schizophrenia / drug therapy* Thiazoles / adverse effects, pharmacokinetics*, pharmacology* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents; 0/Piperazines; 0/Thiazoles; 146939-27-7/ziprasidone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pegfilgrastim.
Next Document: Candesartan cilexetil: an update of its use in essential hypertension.